Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

CYP2A5/CYP2A6 Expression in Mouse and Human Hepatocytes Treated with Various in Vivo Inducers

Marı́a Teresa Donato, Pirkko Viitala, Cristina Rodriguez-Antona, Aija Lindfors, Jose V. Castell, Hannu Raunio, Maria Jose Gómez-Lechón and Olavi Pelkonen
Drug Metabolism and Disposition November 2000, 28 (11) 1321-1326;
Marı́a Teresa Donato
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pirkko Viitala
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristina Rodriguez-Antona
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aija Lindfors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jose V. Castell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hannu Raunio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Jose Gómez-Lechón
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olavi Pelkonen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Induction of coumarin 7-hydroxylation, catalyzed by CYP2A5 in mice and CYP2A6 in humans by various known in vivo murine inducers and modifiers, was compared in human and mouse hepatocytes in culture. Phenobarbital and rifampicin were efficient inducers (up to 10-fold induction) after 48-h treatment in murine cultured hepatocytes, whereas the enzyme activity in human hepatocytes was much more refractory to induction. However, a prolongation of incubation time to 72 h in human hepatocytes led to a modest restoration of inducibility by phenobarbital. Of the three porphyrinogenic inducers studied, griseofulvin induced the murine enzyme efficiently, but not the human enzyme, whereas aminotriazole and thioacetamide had no effect on either species. Pyrazole produced substantial induction in both human and murine hepatocytes, whereas cobalt chloride, which is also an in vivo inducer of the mouse enzyme, had no effect. Clofibric acid, an in vivo depressor of coumarin 7-hydroxylase, also depressed hepatocyte activities. In both murine and human hepatocytes, changes in CYP2A5/6 mRNA levels correlated roughly with enzyme changes, except in the case of cobalt chloride, which increased mRNA levels despite a lack of effect on enzyme activity. In general, human and mouse hepatocytes gave a similar response to CYP2A inducers. However, some differences were found, which means that, although CYP2A isozymes are probably regulated in a similar manner in both species, it is necessary to be cautious before extrapolating to human the results found in mouse models.

Coumarin 7-hydroxylase activity is catalyzed almost solely by CYP2A5 and CYP2A6 in mouse and human livers, respectively (Pelkonen et al., 1997). Studies on the inducibility of coumarin 7-hydroxylase in mouse liver in vivo have demonstrated that the activity is inducible by a large variety of compounds, including the classic inducers (phenobarbital, rifampicin), pyrazole and its derivatives and porphyrinogenic substances (thioacetamide, aminotriazole, griseofulvin, cobalt chloride). CYP2A5 activity is decreased by clofibrate, a representative peroxisome proliferator in rodent liver (Kojo et al., 1996).

Much less is known about the inducibility of CYP2A6 in humans. Coumarin has proven to serve as an excellent probe for the in vivo characterization of human CYP2A6-associated metabolism (Rautio et al., 1992). Antiepileptic drug therapy with carbamazepine, clonazepam, phenobarbital, and phenytoin was associated in humans with an increased capacity to form 7-hydroxycoumarin from coumarin, thus indicating CYP2A6 induction in vivo (Sotaniemi et al., 1995). In human cultured hepatocytes, at least phenobarbital and rifampicin are capable of inducing CYP2A6 (Dalet-Beluche et al., 1992).

A mouse primary hepatocyte model was used to study induction and regulation of CYP2A5 on a chemically defined, controllable environment (Salonpää et al., 1994). Earlier studies have demonstrated that phenobarbital and some other in vivo inducers also increased CYP2A5 in hepatocytes in vitro, but several other efficient in vivo inducers did not increase CYP2A5 expression in primary hepatocytes, which indicates profound differences in the way the induction is controlled in vivo and in isolated hepatocytes (Salonpää et al., 1997).

To uncover the potential inducing effects of several of the above-mentioned substances on human CYP2A6-associated coumarin 7-hydroxylase activity, we utilized human primary hepatocytes in culture and compared the inducibility of coumarin 7-hydroxylase in human and murine hepatocytes. This comparison revealed that there are at least quantitative, if not qualitative, differences between human and murine hepatocytes in their responses to murine in vivo inducers.

Experimental Procedures

Materials.

William's medium E, insulin-transferrin-selenate media supplement (ITS),1dexamethasone, bovine serum albumin, and coumarin were obtained from Sigma Chemical Co. (St. Louis, MO). Insulin was from Lilly (Indianapolis, IN), collagenase was from Worthington Biochemical (Freehold, NJ). Fetal calf serum (FCS), newborn calf serum, Ham F-12 and Leibovitz L-15 culture media, and gentamicin were from Life Technologies, Inc. (Paisley, Scotland).

Isolation and Culture of Hepatocytes.

Human hepatocytes were obtained from surgical liver biopsies (weighing 1–3 g) of patients undergoing cholecystectomy after informed consent was obtained. Patients had no known liver pathology, and they did not receive any medication during the weeks before surgery. The patients were not habitual consumers of alcohol or other drugs. A total of 16 liver biopsies (8 males and 8 females) were used (Table1). The ages of the patients ranged from 32 to 82 years. Hepatocytes were isolated using a two-step microperfusion technique of the tissue as described elsewhere (Gómez-Lechón et al., 1997). Cellular viability, estimated by the dye exclusion test with 0.4% trypan blue in saline, was higher than 90%. Hepatocytes were seeded on fibronectin-coated plastic dishes (3.5 μg/cm2) at a density of 8 × 104 viable cells/cm2 and cultured in Ham's F-12/Lebovitz L-15 (1:1) medium supplemented with 2% newborn calf serum, 10 mM glucose, 50 mU/ml penicillin, 50 μg/ml streptomycin, 0.2% bovine serum albumin, and 10 nM insulin. One hour later the medium was changed, and after 24 h the cells were shifted to serum-free, hormone-supplemented medium (10 nM insulin and 10 nM dexamethasone). The medium was changed daily. Under these culture conditions the cells are metabolically competent (Donato et al., 1995;Gómez-Lechón et al., 1997).

View this table:
  • View inline
  • View popup
Table 1

Basal coumarin 7-hydroxylase activities in human hepatocytes (n = 16)

Mouse hepatocytes were obtained from male DBA/2 mice, aged 7 to 10 weeks. To isolate hepatocytes, mouse livers were perfused with collagenase solution as described previously (Salonpää et al., 1994, 1997). After filtration and centrifugation (50g, 2 min), the isolated hepatocytes were dispersed in William's medium E containing dexamethasone (20 ng/ml), ITS (insulin 5 mg/l, transferrin 5 mg/l, sodium selenate 5 μg/l), gentamicin (10 μg/ml), and 10% FCS at a density of 5 × 106 cells/90-mm plasma-treated plastic dish (Falcon 3003). The cultures were maintained at 37°C in a humidified incubator. After 2 to 3 h, nonattached cells were discarded by aspiration, followed by changing the medium to William's E without FCS.

Incubation of Hepatocytes with Potential Inducers.

Dose-response curves for cytotoxicity and enzymatic activity induction were obtained by incubating hepatocytes with increasing concentrations of the compounds up to the highest nontoxic concentration. Treatment of human hepatocytes was started at 24 h of culture, and cells were incubated in the presence of inducers for 48 h (in a few experiments up to 72 h). In mouse hepatocytes, compounds were added to the culture medium just after the cells were attached to the plates, which occurred 2 to 3 h after plating. Cells were then incubated for 48 h.

The cytotoxicity of the studied compounds in hepatocytes was estimated as follows. Human hepatocytes were seeded on 96-well microtiter plates and treated with a wide range of concentrations of the compounds. Cellular viability was assessed at the end of the treatments by the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) test in as described in detail elsewhere (Borenfreund et al., 1988). The maximal noncytotoxic concentration was estimated from the dose-response curves. Cytotoxicity on mouse hepatocytes was estimated earlier (Salonpää et al., 1997; Viitala, 1997). The cytotoxicity of the studied compounds was usually caused by roughly similar concentrations. In the case of aminotriazole and thioacetamide, murine hepatocytes seemed to be about twice as sensitive as human hepatocytes.

For CYP2A6 mRNA determination by reverse transcriptase-polymerase chain reaction (PCR), treatment was started at 24 h, and cells were incubated only for the following 24 h. Control cultures were treated with the same final concentration of the solvents. For mRNA analysis by the Northern technique in mouse hepatocytes, treatment with studied compounds began 2 to 3 h after plating, when the cells were attached, and lasted for 48 h.

Enzyme Activity Assay.

Coumarin 7-hydroxylation (COH) was determined directly in living human hepatocytes cultured on 96-well plates as previously described (Donato et al., 1998a). In brief, monolayers were washed twice with phosphate-buffered saline, 20 mM, pH 7.4, to remove detached cells, hepatocytes were incubated with culture medium containing 50 μM coumarin for 1 h at 37°C, and 7-hydroxycoumarin was enzymatically deconjugated and quantified fluorimetrically in aliquots of culture medium. Cellular protein was determined by the Lowry method (1951) adapted to 96-well plates in our laboratory.

Coumarin 7-hydroxylase in mouse hepatocytes was assayed as follows. After 48 h in culture, mouse hepatocytes were scraped, washed, suspended in 200 μl of phosphate-buffered saline and sonicated. Cellular protein contents were determined according to Bradford (1976). COH activity was measured as described previously (Aitio, 1978) using 100 μM coumarin as substrate. Because the absolute values of enzyme catalytic activities varied from one batch of cells to another, activities are given relative to the respective control values, which were normalized to 100%.

Analysis for Specific mRNA.

In the case of human hepatocytes, RNA purification and cDNA synthesis were performed as described by Jover et al. (1996). Forward and reverse primers selected for human CYP2A6 and β-actin and/or glucose-6-phosphate dehydrogenase as an internal control for data normalization are presented in Table2. A sample of the appropriately diluted cDNA was added to 27 μl of the reaction mixture (final concentrations: 10 mM Tris-HCl, pH 8.8, 50 mM KCl, 1.5 mM MgCl2, 0.1% Triton X-100, 60 μM each deoxynucleotide triphosphate, 1 U of Taq DNA polymerase, and 0.2 μM each primer). Amplification was programmed for an initial denaturation of 4 min at 94°C, followed by 30 cycles of 45 s at 94°C, 45 s at 60°C, 1 min at 72°C, and a final extension of 5 min at 72°C. Appropriate dilutions were empirically determined for each cDNA to ensure that the resulting PCR products derived only from the exponential phase of the amplification. Under these conditions, the yield of the PCR product was found to be proportional to the input cDNA (Jover et al., 1997). For quantitative analysis, aliquots of the PCR reaction were subjected to electrophoresis on 1.2% agarose gel, and the products were visualized by ethidium bromide staining. The gel image was digitalized, and the band intensity was quantified.

View this table:
  • View inline
  • View popup
Table 2

Oligonucleotides

To measure CYP2A5 mRNA, adherent mouse hepatocytes were scraped, washed, and homogenized in 400 μl of extraction buffer. mRNA was purified by Quick-Prep Micro mRNA purification kit (Amersham Pharmacia Biotech, Uppsala, Sweden). Purified mRNA was separated on a 1% agarose gel and transferred to Qiabrane nylon membrane (Qiagen, Chatsworth, CA). RNA was fixed by UV-crosslinking in UV Stratalinker 1800 (Stratagene, San Diego, CA), and the membrane was hybridized to a [32P]dCTP-labeled ClaI-cut fragment of CYP2A5 cDNA. Radioactivity was measured with PhosphorImager SI equipment (Molecular Dynamics, Sunnyvale, CA).

Statistical Analysis.

Each assay was carried out in at least three different cell preparations, and each determination was done in four plates (eight wells for cytotoxicity experiment) from each culture. The results shown are the mean value ± S.E.M. Data were analyzed with the Student's t test. Values of P < .05 were considered significant.

Results

Basal Activity Values in Human and Murine Hepatocytes.

Coumarin 7-hydroxylase activities in basal conditions were measured for both human and murine hepatocytes. To measure coumarin 7-hydroxylase activity and inducibility in human hepatocytes, cells obtained from 16 different individuals were studied. The human values shown in Table 1correspond to basal activity at 72 h of culture. It can be observed that the basal coumarin 7-hydroxylase activity exhibited a rather large variability, from 1 to about 20 pmol/mg of cellular protein per minute, i.e., a 20-fold variation (Table 1). Basal activity at 24 h of culture ranged from 1.7 to 26.8 pmol/mg/min.

Similar coumarin 7-hydroxylase activity levels were found in male DBA/2 mouse cultured hepatocytes. In murine hepatocytes, a 72-h incubation tends to lead in many cases to an apparent decrease in viability and a rather drastic decrease in coumarin 7-hydroxylase activity and inducibility, and consequently the 24- and 48-h values are given: at 24 h in culture the average value for eight different hepatocyte preparations was 4.9 pmol/mg/min (with a range of 1.4–8.8), and after 48 h, the average value of coumarin 7-hydroxylase activity was 3.1 pmol/mg/min (ranging between 1.3 and 8.7).

Effect of Murine in Vivo Inducers/Depressors on Coumarin 7-Hydroxylase Activity in Human and Mouse Hepatocytes.

The inducibility of coumarin 7-hydroxylase in human and murine hepatocytes in cultures after exposure of the cells for 48 h (in some cases for 72 h in human hepatocytes) to the studied substances is summarized in Table 3. The figures in Table 3 show the highest concentration of the compound that could be used without overt cytotoxicity. In principle, similar concentration ranges in human and murine hepatocytes were studied.

View this table:
  • View inline
  • View popup
Table 3

Effect of murine in vivo inducers/depressors on COH activity in human and mouse hepatocytes

Two classical inducers, phenobarbital and rifampicin, were incubated with both human and mouse hepatocytes. In murine hepatocytes, phenobarbital induced a severalfold increase in coumarin 7-hydroxylase activity (3.8-fold on average; maximum 10-fold) (Table 3). This finding is consistent with those of earlier studies in our laboratory (Salonpää et al., 1994). On the other hand, human hepatocytes (various concentrations in hepatocytes from five different individuals, BH346, -348, -350, -352, and -373, were employed) were much more resistant to phenobarbital induction. The difference after 48-h incubation seems significant, because 7-benzyloxyresorufinO-dealkylase, a CYP2B6 activity, was clearly inducible (2.2-fold over control activity) in two of the human hepatocyte cultures (BH348 and -373), which indicates that human hepatocytes were intrinsically inducible by phenobarbital. When the incubation time with phenobarbital was increased to 72 h, a clear increase (2.2-fold) in coumarin 7-hydroxylase activity was observed as compared with the control value of BH351 (Table 3).

With rifampicin as an inducer, up to 6.1-fold induction was seen in murine hepatocytes, whereas no induction was observed in human hepatocytes (one or more concentration in five individual cultures; BH346, -348, -350, -351, and -373). Prolongation of treatment time to 72 h did not result in an induction in human hepatocytes (Table3). In contrast, treatment of human hepatocytes with 50 μM rifampicin for 48 h produced a significant increase in testosterone 6β-hydroxylation, a CYP3A4 activity (2.3-fold over control as average).

Pyrazole and cobalt are two reasonably well studied inducers of coumarin 7-hydroxylase in mouse liver in vivo (Viitala, 1997). Actually, cobalt chloride was one of the first demonstrated in vivo inducers of coumarin 7-hydroxylase (Legrum et al., 1979). Pyrazole induced coumarin 7-hydroxylase activity equally well (up to 10-fold at 20 mM) in both human (five individual cultures: BH342, -338, -339, -370, and -373) and murine hepatocytes (Fig.1). Concentrations needed for detectable induction are rather high, i.e., over 500 μM.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

The effect of pyrazole on coumarin 7-hydroxylase activity in cultured primary human and murine hepatocytes.

Human (circles) and mouse (squares) cultured hepatocytes were exposed to increasing concentrations of pyrazole, and COH activity was assayed 48 h later as described under Experimental Procedures. Values correspond to mean ± S.E. of three different hepatocyte cultures. Results are expressed relative to COH activity in control cells. *P < .05.

After the 48-h treatment, cobalt chloride did not induce coumarin 7-hydroxylase activity in either human or mouse hepatocytes in culture. However, prolongation of treatment time to 72 h led to a modest increase in coumarin 7-hydroxylation (about 1.8-fold over the control activity in human hepatocytes, Table 3).

Earlier we demonstrated that many porphyrinogenic substances (griseofulvin, thioacetamide, aminotriazole) are good inducers of coumarin 7-hydroxylase in mouse liver in vivo (Viitala, 1997). In murine hepatocytes, griseofulvin was a potent inducer of coumarin 7-hydroxylase, with up to a 6-fold induction at 100 μM on average, whereas very little induction (1.5-fold) was seen in human hepatocytes (four individual cultures) (Fig. 2).

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2

The effect of griseofulvin on coumarin 7-hydroxylase activity in cultured primary human and murine hepatocytes.

Human (circles) and mouse (squares) cultured hepatocytes were exposed to increasing concentrations of griseofulvin, and COH activity was assayed 48 h later as described under Experimental Procedures. Values correspond to mean ± S.E. of three to five different hepatocyte cultures. Results are expressed relative to COH activity in control cells. *P < .05.

At concentrations below 1 mM aminotriazole, there was no indication of induction in either human or mouse hepatocytes. At 2 mM, a 2-fold induction of the activity was seen in one human hepatocyte culture (BH370). Prolongation of treatment to 72 h resulted in a modest increase of enzyme activity (1.40–1.8-fold) at concentrations between 50 and 200 μM (Table 3).

Thioacetamide did not induce the enzyme in either human (three individual cultures; BH346, -348, and -352) or murine hepatocytes (Table 3). Instead, a tendency to decreased activities was observed. Prolongation of treatment to 72 h did not result in an increase of activity.

In vivo clofibric acid causes a drastic decrease in coumarin 7-hydroxylase activity in mouse liver (Kojo et al., 1996). In hepatocytes in culture, clofibric acid tended to decrease coumarin 7-hydroxylase activity in both human (four individual cultures; BH346, -348, -350, and -352) and murine hepatocytes in culture (Table 3). No increased effect was observed after a longer treatment time.

Effects of Modifiers on CYP2A5/6 mRNA in Human and Mouse Hepatocytes.

The effects of the different compounds on CYP2A5 and CYP2A6 mRNA levels were also examined in cultured murine and human hepatocytes, respectively. As seen in Fig. 3, treatment of mouse hepatocytes with fenobarbital, rifampicin, pyrazole, cobalt chloride, and griseofulvin produced marked increases in the amount of specific CYP2A5 mRNA. These effects correspond to increases in the catalytic activity (Figs. 1 and 2; Table 3). A noteworthy exception was cobalt chloride, which was unable to induce the catalytic activity but increased the amount of mRNA. An explanation might be that the up-regulation of the CYP2A5 enzyme by cobalt chloride is somehow blocked after the increase in mRNA.

Figure 3
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3

The effect of various coumarin 7-hydroxylase modifiers on CYP2A5/CYP2A6 mRNA in cultured primary murine and human hepatocytes.

C, control; PB, 1.5 mM (murine)/2.0 mM (human) phenobarbital; RIF, 10 μM/25 μM rifampicin; PYR, 10 mM/10 mM pyrazole; CO, 10 μM/100 μM cobalt; GR, 100 μM/100 μM griseofulvin; ATA, 100 μM/50 μM aminotriazole; TA, 10 μM/25 μM thioacetamide; CLOF, 100 μM/750 μM clofibrate. Values correspond to mean ± S.E. of two to seven different hepatocyte cultures. Results are expressed relative to CYP2A5/CYP2A6 mRNA levels in control cells.*P < .05.

A good correlation between the effects on CYP2A6 mRNA levels and coumarin 7-hydroxylase activity was also found in human hepatocytes (Figs. 1-3; Table 3). Comparison of the results obtained in primary cultured hepatocytes from both species revealed that exposure of cells to the different compounds produced, in general, lower effects on human hepatocytes than on mouse hepatocytes.

Discussion

Most studies on the effects of chemical inducers on CYP isozymes have been done on laboratory animals. In particular, regulation of coumarin 7-hydroxylase catalyzed by CYP2A5 in mouse liver has been extensively characterized, but comparison with what happens to the orthologous CYP2A6 enzyme in human liver has been lacking. Human hepatocyte cultures provide a valuable experimental model for studying the mechanisms involved in the regulations of CYP isozymes in humans. Cultured hepatocytes from different donors exhibit a rather wide variability in coumarin 7-hydroxylase activity (about 20-fold, Table 1) that can be related to the marked interindividual differences in CYP2A6 protein levels and activity observed in human liver (Yun et al., 1991;Rautio et al., 1992). It has been suggested that these large variations differences might be due to CYP2A6 inducibility by certain drugs or environmental and nutritional factors (Cashman et al., 1992) or to genetic polymorphism (Fenandez-Salguero et al., 1995; Pelkonen et al., 1997). In the present study, we show that a number of compounds, including classic CYP inducers, metal ions, and porphyrinogenic agents, increased CYP2A6 activity at mRNA levels in human hepatocytes in primary culture, and these results suggest that those compounds could act as inducers of CYP2A6 in human liver. Comparative studies in human and mouse hepatocytes showed that effects on CYP2A5 and CYP2A6 were similar, which means that the two isozymes might be regulated in a similar manner in both species. Only rifampicin displayed a different action in both species; it induces CYP2A5 enzyme in murine hepatocytes but seems to have no effect on human cells.

As we have observed earlier with some inducers in mouse in vivo and in hepatocytes, increases in the amount of the specific CYP2A5 mRNA corresponded roughly to increases in the catalytic activity (Hahnemann et al., 1992; Salonpää et al., 1992, 1995, 1997; Kojo et al., 1998). Whether this increase is transcriptional or post-transcriptional is not known in most cases. There is some evidence that phenobarbital is a transcriptional inducer (Aida and Negishi, 1991; Hahnemann et al., 1992), whereas pyrazole might act post-transcriptionally (Geneste et al., 1996; Tilloy-Ellul et al., 1999). In the present study a noteworthy exception was cobalt chloride, which was unable to induce the catalytic activity but increased the amount of mRNA severalfold. This finding is in contradiction with our earlier in vivo study in mice, where cobalt chloride increased both coumarin 7-hydroxylase activity and CYP2A5 mRNA (Kocer et al., 1991;Hahnemann et al., 1992). A possible explanation might be that in murine hepatocytes the up-regulation of CYP2A5 enzyme by cobalt chloride is somehow blocked after the increase in mRNA.

Most inducers of CYP2A5 in murine hepatocytes were also efficient inducers of CYP2A6 in human hepatocytes, although CYP2A6 seemed to be much more refractory to the induction than CYP2A5. In particular, after 48-h treatment with phenobarbital, coumarin 7-hydroxylase remained at the control level in human hepatocytes, whereas it was increased at least 3-fold, and even 10-fold in some cultures, in murine hepatocytes. Phenobarbital is, however, intrinsically able to induce CYP enzymes in human hepatocytes, because: 1) an induction in 7-benzyloxyresorufin O-dealkylase activity and CYP2B6 mRNA levels was demonstrated at 48 h (Rodriguez-Antona et al., 2000); 2) incubation of human hepatocytes for 72 h in the presence of phenobarbital increased coumarin 7-hydroxylase activity about 2-fold; and 3) increased levels of CYP2A6 mRNA were found. The mechanism by which phenobarbital induces murine CYP2A5 is insufficiently known, but studies from our laboratory point to a possible role of cAMP-mediated signal transduction (Salonpää et al., 1994, 1997). It may be that culturing human hepatocytes lead to a loss of or a decrease in an important mediator for CYP2A6 induction by phenobarbital, which, however, is not necessary for the phenobarbital induction of other responsive CYPs. The loss is relative, because a longer incubation leads at least to a partial restoration of inducibility. In the case of rifampicin, strong differences between human and mouse hepatocytes were found. Rifampicin is an efficient in vitro inducer of CYP2A5, but it does not produce any changes in CYP2A6 activity and mRNA levels. In contrast, treatment of cultured human hepatocytes with rifampicin resulted in increased CYP3A4 activity that correlates with an induction of CYP3A4 protein and specific mRNA levels (Donato et al., 1998b; Rodriguez-Antona et al., 2000), which indicates that human hepatocytes are able to respond to rifampicin treatment.

In conclusion, both similarities and differences in regulation of CYP2A enzymes in mouse and human hepatocytes were demonstrated. As such, this conclusion is not surprising considering the large species differences in CYP enzymes between, for example, rodent and human. However, as reviewed more extensively elsewhere (Fernandez-Salguero et al., 1995;Fernandez-Salguero and Gonzalez, 1995; Pelkonen et al., 1997), human and mouse CYP2A-associated coumarin 7-hydroxylases display relatively similar characteristics in terms of both enzymatic and regulatory properties. The pharmacological and toxicological consequences of this induction of human CYP2A6 induction can be clinically relevant. Inducers can influence the metabolism of therapeutic agents simultaneously or subsequently administered, and this can alter their efficacy or increase their toxicity. Human CYP2A6 is involved in the oxidation of drugs, including coumarin and nicotine (Yun et al., 1991;Cashman et al., 1992), as well as in the metabolic activation of certain carcinogenic and toxic chemicals (Yun et al., 1991). Ultimately, it is the balance between bioactivation, detoxication, and defense mechanisms that determines the susceptibility of an organism to drugs and other xenobiotics.

Acknowledgments

The skillful technical assistance of Päivi Tyni, Ritva Tauriainen, Carmen Lorenzo, and Epifania Belenchón is gratefully acknowledged.

Footnotes

  • Send reprint requests to: Maria Jose Gómez-Lechón, Unidad de Hepatologı́a Experimental, Centro de Investigation, Hospital Universitario La Fe, Avda. Campanar 21, Valencia E-46009, Spain. E-mail: Gomez_mjo{at}gva.es

  • This work was supported by grants from the Emil Aaltonen Foundation, the ALIVE Foundation, and the EU-Biomed2 program of European Commission (“EUROCYP”). The study was performed within the framework of the Action COST B1.

  • Abbreviations used are::
    ITS
    insulin-transferrin-selenate media supplement
    CYP
    cytochrome P-450
    COH
    coumarin 7-hydroxylase
    FCS
    fetal calf serum
    MTT
    3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
    PCR
    polymerase chain reaction
    • Received May 19, 2000.
    • Accepted July 31, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    1. Aida K,
    2. Negishi M
    (1991) Post-transcriptional regulation of coumarin 7-hydroxylase (P450Coh) induction by xenobiotics in mouse liver: mRNA stabilization by pyrazole. Biochemistry 30:8041–8045.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Aitio A
    (1978) A simple and sensitive assay of 7-ethoxycoumarin deethylation. Anal Biochem 85:488–491.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Borenfreund H,
    2. Babich H,
    3. Martin-Alguacil N
    (1988) Comparisons of two in vitro cytotoxicity assays—the neutral red (NR) and tetrazolium MTT tests. Toxicol in Vitro 2:1–6.
  4. ↵
    1. Bradford MM
    (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Cell 72:248–254.
  5. ↵
    1. Cashman JR,
    2. Park SB,
    3. Yang ZC,
    4. Wrighton SA,
    5. Jacob P,
    6. Benowitz NL
    (1992) Metabolism of nicotine by human liver microsomes: Stereoselective formation of trans-nicotine N′-oxide Chem Res Toxicol 5:639–646.
  6. ↵
    1. Dalet-Beluche I,
    2. Boulenc X,
    3. Fabre G,
    4. Maurel P,
    5. Bonfils C
    (1992) Purification of two cytochrome P450 isozymes related to CYP2A and CYP3A gene families from monkey (baboon, Papio papio) liver microsomes: Cross reactivity with human forms. Eur J Biochem 204:641–648.
    OpenUrlPubMed
  7. ↵
    1. Donato MT,
    2. Castell JV,
    3. Gómez-Lechón MJ
    (1995) Effect of model inducers on cytochrome P450 activities of human hepatocytes in primary cultures. Drug Metab Dispos 23:553–558.
    OpenUrlAbstract
  8. ↵
    1. Donato MT,
    2. Castell JV,
    3. Gómez-Lechón MJ
    (1998a) Coumarin 7-hydroxylation microassay in intact cells cultured in 96-well plates. ATLA 26:213–223.
  9. ↵
    1. Donato MT,
    2. Gómez-Lechón MJ,
    3. Jover R,
    4. Nakamura T,
    5. Castell JV
    (1998b) Human hepatocyte growth factor down-regulates the expression of cytochrome P450 isozymes in human hepatocytes in primary culture. J Pharmacol Exp Ther 284:760–767.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Fernandez-Salguero P,
    2. Gonzalez FJ
    (1995) The CYP2A gene subfamily: Species differences, regulation, catalytic activities and role in chemical carcinogenesis. Pharmacogenetics 5:S123–S128.
  11. ↵
    1. Fernandez-Salguero P,
    2. Hoffman SMG,
    3. Cholerton S,
    4. Mohrenweiser H,
    5. Raunio H,
    6. Rautio A,
    7. Pelkonen O,
    8. Huang J,
    9. Evans WE,
    10. Idle JR,
    11. Gonzalez FJ
    (1995) A genetic polymorphism in coumarin 7-hydroxylation: Sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 57:651–660.
    OpenUrlPubMed
  12. ↵
    1. Geneste O,
    2. Raffalli F,
    3. Lang MA
    (1996) Identification and characterization of a 44 kDa protein that binds specifically to the 3′ untranslated region of CYP2a5 mRNA: Inducibility, subcellular distribution and possible role in mRNA stabilization. Biochem J 313:1029–1037.
  13. ↵
    1. Castell JV,
    2. Gómez-Lechón MJ
    1. Gómez-Lechón MJ,
    2. Donato MT,
    3. Ponsoda X,
    4. Fabra R,
    5. Trullenque R,
    6. Castell JV
    (1997) Isolation, culture and use of human hepatocytes in drug research. in In Vitro Methods in Pharmaceutical Research, eds Castell JV, Gómez-Lechón MJ (Academic Press, London), pp 129–154.
  14. ↵
    1. Hahnemann B,
    2. Salonpää P,
    3. Pasanen M,
    4. Mäenpää J,
    5. Honkakoski P,
    6. Juvonen R,
    7. Lang MA,
    8. Pelkonen O,
    9. Raunio H
    (1992) Effect of pyrazole, cobalt and phenobarbital on mouse liver cytochrome P-450 2a-4/5 (Cyp2a-4/5) expression. Biochem J 286:289–294.
  15. ↵
    1. Jover R,
    2. Hoffmann K,
    3. Meyer U
    (1997) Induction of 5-aminolevulinate synthase by drugs is independent of increased apocytochrome P450 synthesis. Biochem Biophys Res Commun 226:152–157.
    OpenUrl
  16. ↵
    1. Jover R,
    2. Lindberg RLP,
    3. Meyer U
    (1996) Role of heme in cytochrome P450 transcription and function in mice treated with lead acetate. Mol Pharmacol l50:474–481.
    OpenUrlAbstract
  17. ↵
    1. Kocer Z,
    2. Raunio H,
    3. Pasanen M,
    4. Arvela P,
    5. Raiskila T,
    6. Honkakoski P,
    7. Lang MA,
    8. Negishi M,
    9. Pelkonen O
    (1991) Comparison between cobalt and pyrazole in the increased expression of coumarin 7-hydroxylase in mouse liver. Biochem Pharmacol 41:461–465.
  18. ↵
    1. Kojo A,
    2. Pellinen P,
    3. Juvonen R,
    4. Raunio H,
    5. Pelkonen O,
    6. Pasanen M
    (1996) Distinct responses of mouse hepatic CYP enzymes to corn oil and peroxisome proliferators. Biochem Pharmacol 51:1137–1143.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Kojo A,
    2. Viitala P,
    3. Pasanen M,
    4. Pelkonen O,
    5. Raunio H,
    6. Juvonen R
    (1998) Induction of CYP2A5 by pyrazole and its derivatives in mouse primary hepatocytes. Arch Toxicol 72:336–346.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Legrum W,
    2. Stuehmeier G,
    3. Netter KJ
    (1979) Cobalt as a modifier of microsomal monooxygenase in mice. Toxicol Appl Pharmacol 48:195–204.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Lowry OH,
    2. Rosebrough NJ,
    3. Farr AL,
    4. Randall RJ
    (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275.
    OpenUrlFREE Full Text
  22. ↵
    1. O'Kennedy R,
    2. Thornes RD
    1. Pelkonen O,
    2. Raunio H,
    3. Rautio A,
    4. Pasanen M,
    5. Lang MA
    (1997) The metabolism of coumarin. in Coumarins: Biology, Applications and Mode of Action, eds O'Kennedy R, Thornes RD (John Wiley, Chichester), pp 67–92.
  23. ↵
    1. Rautio A,
    2. Kraul H,
    3. Kojo A,
    4. Salmela E,
    5. Pelkonen O
    (1992) Interindividual variability of coumarin 7-hydroxylation in healthy individuals. Pharmacogenetics 2:227–233.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Rodriguez-Antona C,
    2. Jover R,
    3. Gómez-Lechón MJ,
    4. Castell JV
    (2000) Quantitative RT-PCR measurement of human cytochrome P-450s: Application to drug induction studies. Arch Biochem Biophys 376:109–116.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Salonpää P,
    2. Iscan M,
    3. Pasanen M,
    4. Arvela P,
    5. Pelkonen O,
    6. Raunio H
    (1992) Cerium-induced strain-dependent increase in CYP2a-4/5 (cytochrome P4502a-4/5) expression in the liver and kidneys of inbred mice. Biochem Pharmacol 44:1269–1274.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Salonpää P,
    2. Kottari S,
    3. Pelkonen O,
    4. Raunio H
    (1997) Regulation of CYP2A5 induction by porphyrinogenic agents in mouse primary hepatocytes. Naunyn-Schmiedeberg's Arch Pharmacol 355:8–13.
    OpenUrlPubMed
  27. ↵
    1. Salonpää P,
    2. Krause K,
    3. Pelkonen O,
    4. Raunio H
    (1995) Up-regulation of CYP2A5 expression by porphyrinogenic agents in mouse liver. Naunyn-Schmiedeberg's Arch Pharmacol 351:446–452.
    OpenUrlPubMed
  28. ↵
    1. Salonpää P,
    2. Pelkonen O,
    3. Kojo A,
    4. Pasanen M,
    5. Negishi M,
    6. Raunio H
    (1994) CYP2A5 expression and inducibility by phenobarbital is modulated by cAMP in mouse primary hepatocytes. Biochem Biophys Res Commun 205:631–637.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Sotaniemi EA,
    2. Rautio A,
    3. Bäckström M,
    4. Arvela P,
    5. Pelkonen O
    (1995) Hepatic cytochrome P450 isozyme (CYP2A6 and CYP3A4) activities and fibrotic process in liver. Br J Clin Pharmacol 39:71–76.
    OpenUrlPubMed
  30. ↵
    1. Tilloy-Ellul A,
    2. Raffalli-Mathieu F,
    3. Lang M
    (1999) Analysis of RNA-protein interactions of mouse liver cytochrome P4502A5 mRNA. Biochem J 339:695–703.
  31. ↵
    1. Viitala P
    (1997) Regulation of the Expression of CYP2A5 in the Mouse. Academic dissertation; (University of Oulu), , 66 pp..
  32. ↵
    1. Yun CH,
    2. Shimada T,
    3. Guengerich FP
    (1991) Purification and characterization of human liver microsomal cytochrome P4502A6. Mol Pharmacol 40:679–685.
    OpenUrlAbstract
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 28 (11)
Drug Metabolism and Disposition
Vol. 28, Issue 11
1 Nov 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
CYP2A5/CYP2A6 Expression in Mouse and Human Hepatocytes Treated with Various in Vivo Inducers
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

CYP2A5/CYP2A6 Expression in Mouse and Human Hepatocytes Treated with Various in Vivo Inducers

Marı́a Teresa Donato, Pirkko Viitala, Cristina Rodriguez-Antona, Aija Lindfors, Jose V. Castell, Hannu Raunio, Maria Jose Gómez-Lechón and Olavi Pelkonen
Drug Metabolism and Disposition November 1, 2000, 28 (11) 1321-1326;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

CYP2A5/CYP2A6 Expression in Mouse and Human Hepatocytes Treated with Various in Vivo Inducers

Marı́a Teresa Donato, Pirkko Viitala, Cristina Rodriguez-Antona, Aija Lindfors, Jose V. Castell, Hannu Raunio, Maria Jose Gómez-Lechón and Olavi Pelkonen
Drug Metabolism and Disposition November 1, 2000, 28 (11) 1321-1326;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Experimental Procedures
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Warfarin PBPK Model with TMDD Mechanism
  • Identification of payload-containing catabolites of ADCs
  • PK Interactions of Licorice with Cytochrome P450s
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics